Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Christopher H. Cabell net worth and biography

Christopher Cabell Biography and Net Worth

CMO of Arena Pharmaceuticals

Dr. Christopher H. Cabell FACC, M.D., MHS is the Advisor at Arena Pharmaceuticals Inc.

What is Christopher H. Cabell's net worth?: The estimated net worth of Christopher H. Cabell is at least $1.30 million as of July 15th, 2020. Dr. Cabell owns 13,000 shares of Arena Pharmaceuticals stock worth more than $1,299,870 as of April 20th. This net worth estimate does not reflect any other investments that Dr. Cabell may own. Learn More about Christopher H. Cabell's net worth.
How do I contact Christopher H. Cabell?: The corporate mailing address for Dr. Cabell and other Arena Pharmaceuticals executives is 6154 Nancy Ridge Drive, San Diego CA, 92121. Arena Pharmaceuticals can also be reached via phone at (858) 453-7200 and via email at [email protected]. Learn More on Christopher H. Cabell's contact information.
Has Christopher H. Cabell been buying or selling shares of Arena Pharmaceuticals?: Christopher H. Cabell has not been actively trading shares of Arena Pharmaceuticals during the last ninety days. Most recently, Christopher Cabell sold 13,000 shares of the business's stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $68.00, for a transaction totalling $884,000.00. Following the completion of the sale, the chief marketing officer now directly owns 13,000 shares of the company's stock, valued at $884,000. Learn More on Christopher H. Cabell's trading history.
Who are Arena Pharmaceuticals' active insiders?: Arena Pharmaceuticals' insider roster includes Vincent Aurentz (VP), Christopher Cabell (CMO), Jayson Dallas (Director), Robert Lisicki (EVP), Amit Munshi (CEO), Tina Nova (Director), and Manmeet Soni (Director). Learn More on Arena Pharmaceuticals' active insiders.

Christopher H. Cabell Insider Trading History at Arena Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/15/2020	Sell	13,000	$68.00	$884,000.00	13,000

Christopher H. Cabell Buying and Selling Activity at Arena Pharmaceuticals

Arena Pharmaceuticals Company Overview

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $99.99

$99.99

50 Day Range

MA: $97.65

$93.13

$99.99

2 Week Range

Now: $99.99

$45.50

$100.00

Volume

107 shs

Average Volume

1,561,326 shs

Market Capitalization

$6.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad